capecitabine + bevacizumab

DRUG2 trials

Sponsors

Dutch Colorectal Cancer Group, Institut de Recherches Internationales Servier

Conditions

Colorectal Cancer MetastaticMetastatic Colorectal Cancer

Phase 2

A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy

CompletedNCT02743221

Institut de Recherches Internationales ServierMetastatic Colorectal Cancer

Start: 2016-04-29End: 2020-09-01Updated: 2024-08-20

Phase 3

Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma

Dutch Colorectal Cancer GroupColorectal Cancer Metastatic

Start: 2007-01-31End: 2013-12-31Target: 635Updated: 2013-12-12

Related Papers

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

British Journal of Cancer2022-04-1916 citations

Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis on the overall survival.

Journal of Clinical Oncology2021-01-207 citations

Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study.

2020-06-0145 citations

QoL from TASCO1: Health-related quality of life of trifluridine/tipiracil-bevacizumab and capecitabine-bevacizumab as first-line treatments in metastatic colorectal cancer patients not eligible for intensive chemotherapy—Results from the TASCO1 phase II study.

Journal of Clinical Oncology2019-01-292 citations

Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.

2017-09-0151 citations

Impact of skeletal muscle index (SMI) loss during palliative systemic treatment (Tx) on time to progression and overall survival (OS) in metastatic colorectal cancer (mCRC) patients.

Journal of Clinical Oncology2017-05-206 citations

Predictive value of <i>KRAS</i> mutation status in metastatic colorectal cancer (mCRC) patients treated with capecitabine and bevacizumab (CAP-B) maintenance treatment vs observation in the phase III CAIRO3 study.

Journal of Clinical Oncology2016-05-203 citations

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

2015-04-07360 citations

Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2014-01-2046 citations

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

2011-06-05171 citations